For example, SPRY4 affects cell growth as a downstream effector of Wnt7A/Fzd9 signaling in ovarian cancer (Chen et al., 2017), breast cancer (Tian et al., 2018), colorectal cancer (Bienz and Clevers, 2000) and prostate cancer (Bisson and Prowse, 2009). Here, SPRY4 is linked to ovarian carcinoma.